CAR-T Therapy China

09/07/2025

CARTEYVA (relmacabtagene autoleucel), also known as relma-cel, is a groundbreaking CD19-targeted CAR-T cell therapy approved by the China National Medical Products Administration (NMPA) for the treatment of large B-cell lymphoma. This cutting-edge therapy received approval in 2021 and has quickly emerged as a key option for patients seeking long-term remission with a favorable safety profile.

In this video, leading hematologists across China share their congratulations and insights on the successful commercialization of CARTEYVA. Their voices reflect the excitement surrounding this milestone in cancer immunotherapy.

💡 Why China?
With top-tier research, world-class clinical expertise, and greater accessibility, China has become the best destination for patients looking for high-quality yet affordable CAR-T cell therapies like Carteyva.

👉 Subscribe to our channel for more updates on CAR-T cell therapy innovations in China
🔗 For treatment inquiries and expert consultations, contact us directly.

01/07/2025

🌟 Breaking Progress in Lymphoma Treatment! 🌟

Experts across China have come together to share groundbreaking updates on T-cell immunotherapy for aggressive B-cell lymphomas like DLBCL and MCL. With new data showing how bispecific antibodies and CAR-T therapies can improve survival and bring hope to patients with relapsed or refractory disease, these advances are reshaping treatment standards and expanding options for those who need them most.

👉 Stay tuned as we dive into these expert insights and what they mean for the future of lymphoma care!

✅ T-cell therapy is indicated for patients with LBCL who have relapsed and/or are refractory to first-line treatment. For adult LBCL patients who do not respond to first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy, CAR-T cell therapy is recommended based on drug approval status in China. For third-line and subsequent treatments of LBCL, bispecific antibodies or CAR-T cell therapy may be administered depending on the patient's condition.

✅ For R/R LBCL patients ineligible for ASCT, consider treatment with GemOx or polatuzumab vedotin combined with bispecific antibodies, or CAR-T cell therapy.

✅ Consolidation therapy with ASCT may be considered after salvage treatment with bispecific antibodies.

✅ For R/R LBCL patients at high risk of infection, CRS, or neurological adverse reactions, bispecific antibody therapy is recommended as the first choice.

✅ For R/R LBCL patients with rapid progression, mononuclear cell collection failure, or CAR-T cell manufacturing failure, bispecific antibody therapy may be considered. For R/R LBCL patients with CNS involvement, CAR-T cell therapy or bispecific antibodies may be administered after comprehensive evaluation of multiple factors.

08/05/2025

In a landmark advancement for solid tumor treatment, a CLDN18.2-targeted CAR-T therapy, satri-cel (CT041), has achieved 96.1% disease control rate (DCR) in advanced gastric cancer patients, with plans for a 2025 commercial launch in China. The therapy, recently granted Breakthrough Therapy Designation by China’s NMPA, could become the world’s first approved CAR-T treatment for solid tumors.

05/05/2025

BCMA is a protein found on the surface of most multiple myeloma cells, it is the treatment target in CAR-T cell therapy for multiple myeloma. Learn more about BCMA CAR-T therapy options available in China.

https://cartcellschina.com/news/myeloma-car-t-treatment/a-new-hope-for-multiple-myeloma-understanding-bcma-car-t-therapy/

17/04/2025

Introducing FUCASO (Equecabtagene Autoleucel), an effective CAR T-cell therapy approved for multiple myeloma. This advanced fully human BCMA CAR-T treatment is only available in China.

Contact us at info@cartcellschina.com and get more information about FOCASO.

Fucaso (Equecabtagene Autoleucel) is an innovative CAR-T cell therapy for multiple myeloma. Mrs. Thanyaphat from Thailand has been diagnosed with multiple m...

10/01/2025

The National Medical Products Administration of China (NMPA) granted Breakthrough Therapy Designation for Carteyva (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) .

Carteyva is Breyanzi CAR T cell therapywith a different brand name, it is available only in China.

NMPA granted Breakthrough Therapy Designation for Carteyva (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) .

07/01/2025

Fucaso (Equecabtagene autoleucel), a BCMA-directed chimeric antigen receptor (CAR) T cell therapy, has shown deep, durable responses with a favorable safety profile in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM).

15/10/2024

Professor Huang He introducing the latest development of CAR T-cell therapy in China at the EBMT-EHA 6th European CAR T-cell Meeting.



https://tcellschina.com/an-update-on-the-experience-with-car-t-cell-therapy-in-china/

22/09/2024

Carteyva is a CAR T-cell therapy for the treatment of three types of lymphoma, large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. It is the first CAR T-cell therapy that has been approved for the treatment of three indications.

Carteyva is developed based on the cell processing platform of Breyanzi, which has been approved by the US FDA for the treatment of above types of lymphoma, and CLL/SLL.

Will CLL/SLL be approved indications for Carteyva in China soon?

The China NMPA has approved new indication, mantel cell lymphoma (MCL), to Carteyva (Relma-cel), this is the third indication approved for this innovative CAR T-cell therapy.

17/09/2024

Welcome to the official page of CAR T-cells China. We have been dedicated to sharing information about the latest development of CAR T-cell therapies in China, and helping international patient access these innovative technologies for cancer treatment. We will start to update shortly, stay with us. Hope we can help😀, wish everyone recovers soon!